Hereditary angioedema type 1 or 2

The PBS subsidises lanadelumab for patients with hereditary angioedema type 1 or 2.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lanadelumab under the National Health Act 1953, section 85 for patients aged 12 years or older with hereditary angioedema (HAE) type 1 or 2.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lanadelumab.

Treatment specifics

To be eligible for PBS subsidised treatment with lanadelumab, patients must be treated by a clinical immunologist or a specialist allergist.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised lanadelumab for patients commencing with no previous treatment with C1-esterase inhibitor (C1-INH) or who are commencing from National Blood Authority funded C1-INH to treat hereditary angioedema type 1 or 2 in writing and either:

All written applications must include the completed:

Applying for initial grandfather treatment

For patients who received non-PBS subsidised lanadelumab treatment before 1 December 2021 for hereditary angioedema type 1 or 2, apply for initial grandfather authority approval in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised lanadelumab to treat hereditary angioedema type 1 or 2 can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 10 December 2021